Shares of Eupraxia Pharmaceuticals Inc. (OTCMKTS:EPRXF – Get Free Report) dropped 1.6% on Tuesday . The company traded as low as C$6.66 and last traded at C$6.66. 270,220 shares changed hands during trading, an increase of 3,547% from the average session volume of 7,410 shares. The stock had previously closed at C$6.77.
Eupraxia Pharmaceuticals Stock Down 1.6%
The stock’s fifty day simple moving average is C$6.43 and its 200 day simple moving average is C$7.21.
About Eupraxia Pharmaceuticals
Eupraxia Pharmaceuticals, Inc (OTCMKTS:EPRXF) is a clinical-stage biotechnology company advancing adeno-associated virus (AAV)-based gene therapies for rare inherited metabolic disorders. The firm’s research platform focuses on developing single-administration treatments designed to address the underlying genetic causes of enzyme deficiencies. Eupraxia’s approach leverages targeted gene delivery to restore or supplement critical metabolic functions in patients with life-threatening conditions.
The company’s lead pipeline candidates include EPRX-101 for Ornithine Transcarbamylase (OTC) deficiency and EPRX-102 for methylmalonic acidemia (MMA), both of which are in preclinical or IND-enabling stages.
Further Reading
- Five stocks we like better than Eupraxia Pharmaceuticals
- Asian Market Circuit Breakers Hit Stocks, Not AI Demand
- Riot Platforms Re-Wires the Ledger for a $9B AI Power Play
- Nebius Just Exploded 34% on Blowout Earnings—Is It Time to Buy?
- Joby’s Defense Pivot Accelerates With $500M Resonant Sciences Deal
Receive News & Ratings for Eupraxia Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eupraxia Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
